Overview

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Status:
Active, not recruiting
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Prof. Dr. Christine Mauz-Körholz
University of Giessen
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
Euronet Worldwide
Treatments:
Cyclophosphamide
Dacarbazine
Prednisone
Vincristine